DayTwo is the leader in precision nutrition for metabolic disease using gut microbiome science, AI and virtual clinical support.
DayTwo is a precision nutrition company that uses food as medicine to enable a path to remission for metabolic diseases including diabetes, prediabetes, clinical obesity, NAFLD. DayTwo's groundbreaking scientific discovery, published in CELL (2015) and JAMA (2019) determined that people respond differently to the same food, thus knowing what food “works” for each person is crucial to an effective care plan. DayTwo uses gut microbiome sequencing (stool sample, akin to Cologuard) to create Food Prescriptions™ for each patient which balance blood sugar levels, improve energy, manage hunger, and help members lose weight. The DayTwo virtual care solution is delivered through Certified Diabetes Care and Education Specialists and Registered Dietitians using a digital app to track progress and to communicate with members.DayTwo uses A1C and Time In Range as the primary clinical outcomes, and weight as a secondary outcome. For those who implement the DayTwo protocol, DayTwo offers up to 100% fees-at-risk.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
May 31, 2021 | Series B | £26.30M | 9 | Jacky Abitbol Yair Schindel | — | Detail |
Oct 6, 2019 | Series B | $5M | 3 | Longliv Ventures | — | Detail |
Jun 26, 2019 | Series B | $31M | 8 | 10D aMoon Fund | — | Detail |
Jun 6, 2018 | Series Unknown | — | 1 | — | — | Detail |
Jun 27, 2017 | Series A | $12M | 6 | Johnson & Johnson Marius Nacht | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Jacky Abitbol | Yes | Series B |
Yair Schindel | Yes | Series B |
Longliv Ventures | Yes | Series B |
Marius Nacht | Yes | Series A |
10D | — | Series B |
aMoon Fund | — | Series B |
Cathay Innovation | — | Series B |
La Maison Partners | — | Series B |
Micron Ventures | — | Series B |
Poalim Equity | — | Series B |